# A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Study · id `cardio:ct-nct06993792` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06993792](<https://clinicaltrials.gov/study/NCT06993792>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06993792

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1400 participants.

## Technical summary

Registry record NCT06993792. Randomized; double masking; primary purpose screening. Start 2025-05-15 (actual); primary completion 2027-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose screening
- Phase: Phase 3
- Enrolled: 1400 participants (planned count; ClinicalTrials.gov record NCT06993792, source copy `cardio:ctgov-nct06993792-2026-07-31`, retrieved 2026-10-26)
- Started: 2025-05-15 (actual) (ClinicalTrials.gov record NCT06993792, source copy `cardio:ctgov-nct06993792-2026-07-31`, retrieved 2026-10-26)
- Primary completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT06993792, source copy `cardio:ctgov-nct06993792-2026-07-31`, retrieved 2026-10-26)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT06993792, source copy `cardio:ctgov-nct06993792-2026-07-31`, retrieved 2026-10-26)
- Countries: United States; Argentina; China; Czechia; Germany; Japan; Puerto Rico (ClinicalTrials.gov record NCT06993792, source copy `cardio:ctgov-nct06993792-2026-07-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06993792-2026-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- Condition: Obesity
- Condition: Overweight
- Condition: Type 2 Diabetes
- Intervention (Drug): Orforglipron
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: d43438f7c11bff939428362526bd3fdd2207a2048aab03c94836e32b579c8f8b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
